NeuBase Therapeutics News

NBSEDelisted Stock  USD 1.62  0.17  9.50%   
About 62% of NeuBase Therapeutics' investor base is looking to short. The analysis of current outlook of investing in NeuBase Therapeutics suggests that many traders are alarmed regarding NeuBase Therapeutics' prospects. The current market sentiment, together with NeuBase Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use NeuBase Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
over a year ago at news.google.com         
Neubase Therapeutics Inc Stock Do Analysts Think You Should Buy - InvestorsObserver
Google News at Macroaxis
over a year ago at www.macroaxis.com         
Exercise or conversion by Dietrich Stephan of 93234 shares of NeuBase Therapeutics subject to Rule 1...
Macroaxis News
over a year ago at finance.yahoo.com         
NeuBase Therapeutics to Explore Strategic Alternatives
Yahoo News
over a year ago at bizjournals.com         
Pittsburgh biotech firm amends stock incentive plan
bizjournals News
over a year ago at news.google.com         
Analysts Express Confidence in argenx with Revised Price Targets - Best Stocks
Google News at Macroaxis
over a year ago at news.google.com         
Galmed Pharmaceuticals Ltd Returns to NASDAQ Offering Investors ... - Best Stocks
Google News at Macroaxis
over a year ago at news.google.com         
Where Will Neubase Therapeutics Inc Stock Go Next After It Has Fallen 3.63 percent in a Week - Inves...
Google News at Macroaxis
over a year ago at news.google.com         
Positive Safety Review of Panbela Therapeutics ASPIRE Trial for ... - Best Stocks
Google News at Macroaxis
over a year ago at news.google.com         
What is Wall Streets Target Price for Neubase Therapeutics Inc Stock Friday - InvestorsObserver
Google News at Macroaxis
over a year ago at globenewswire.com         
NeuBase Announces Closing of 5 Million Concurrent Registered Direct Offering and Private Placement P...
Macroaxis News: globenewswire.com
over a year ago at finance.yahoo.com         
NeuBase Announces Closing of 5 Million Concurrent Registered Direct Offering and Private Placement P...
Yahoo News
over a year ago at benzinga.com         
NeuBase Announces Closing of 5 Million Concurrent Registered Direct Offering and Private Placement P...
benzinga news
over a year ago at finance.yahoo.com         
NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors are Non-Immunogenic, Opening th...
Yahoo News
over a year ago at marketwatch.com         
NeuBase Therapeutics Selling Stock and Issuing Warrants
marketwatch News
over a year ago at globenewswire.com         
NeuBase Announces 5 Million Concurrent Registered Direct Offering and Private Placement Priced At-th...
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about NeuBase Therapeutics that are available to investors today. That information is available publicly through NeuBase media outlets and privately through word of mouth or via NeuBase internal channels. However, regardless of the origin, that massive amount of NeuBase data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NeuBase Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NeuBase Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NeuBase Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NeuBase Therapeutics alpha.

NeuBase Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
NeuBase Announces 1-for-20 Reverse Stock Split
06/14/2023
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Consideration for investing in NeuBase Stock

If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios